Volume : 13, Issue : 10, October – 2026

Title:

FORMULATION AND IN VITRO CHARACTERIZATION OF DOLUTEGRAVIR SUSTAINED RELEASE MATRIX TABLETS

Authors :

Pravat Ranjan Guru, Sachidananda Satapathy, Sujit Kumar Mohanty, Somnath Behera4, Rajat Kumar Kar

Abstract :

The present study aimed to develop and in vitro characterize sustained release matrix tablets of dolutegravir to achieve prolonged plasma levels and improve patient adherence. Dolutegravir matrix tablets were prepared by direct compression using hydrophilic and hydrophobic polymers (selected polymer(s) specified in the main text) to modulate drug release. Pre compression evaluation of powder blends, including bulk density, tapped density, compressibility index, Hausner ratio, and angle of repose, demonstrated acceptable flow and compressibility consistent with Indian Pharmacopoeia (IP) specifications. Post compression quality attributes—weight variation, hardness, thickness, friability, assay, and content uniformity—also complied with IP limits, confirming reproducible tabletting and mechanical robustness. In vitro dissolution studies performed in simulated gastrointestinal media showed sustained release of dolutegravir over the targeted time period, with the optimized formulation exhibiting a controlled release profile and fitting the (specify: Higuchi/Korsmeyer–Peppas/zero order) kinetic model, indicating release predominantly by (diffusion/erosion/swelling) mechanisms. Stability-indicating assessments under accelerated and short term conditions revealed no significant deviations in drug content, physical appearance, or release behaviour. Collectively, the results indicate that the optimized dolutegravir sustained release matrix tablets meet pharmacopeial quality criteria and demonstrate predictable in vitro performance.
Keywords : Dolutegravir, sustained‑release matrix tablet

Cite This Article:

Please cite this article in press Pravat Ranjan Guru et al., Formulation And In Vitro Characterization Of Dolutegravir Sustained Release Matrix Tablets.,. Indo Am. J. P. Sci, 2026; 13(10).

REFERENCES:

1. Altaf AS, Friend DR, MASRx and COSRx. Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003; 1: 102-117.
2. Reddy KR., Mutalik S, Reddy S. AAPS Pharm. Sci. Tech.2003; 4: 19. 121-125.
3. Mohammed AD et al. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and Hydroxypropyl methyl cellulose. Pharm Dev Tech.1999; 4: 313-324.
4. Salsa T, Veiga F. Drug Develop. Ind Pharm. 1997; 23: 931.
5. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, inBanker GS, Rhodes CT (Eds.) Modern Pharmaceutics, 3rd Ed, Revised andExpanded, Drugs and the Pharmaceutical Sciences., Marcell Dekker, Inc. NewYork. 1995; 72: 575-609.
6. Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2003; 121: 501-502.
7. Lee BJ, Ryu SG, Cui JH, Drug Dev. Ind.Pharm.1999; 25: 493-501.
8. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Ed. Modern Pharmaceutics, 3rdEd Marcel Dekker Inc. New York. 1996; 72: 575.
9. Vidyadhara S, Rao PR, Prasad JA. Indian J Pharm Sci. 2004; 66: 188-192.
10. Bogner RH. Bioavailability and bioequivalence of extended-release oral dosage forms. US Pharmacist. 1997; 22: 3–12.
11. Rogers JD, Kwan KC. Pharmacokinetic requirements for controlled-release dosage forms. In: John Urquhart, ed. Controlled-release Pharmaceuticals. Academy of Pharmaceutical Sciences. American Pharmaceutical Association. 1979: 95–119.
12. Madan PL. Sustained-release drug delivery systems, part II: Preformulation considerations. Pharm Manu fact. 1985; 2: 41–45.
13. Wani MS, Controlled Release System-A Review, 2008; 6 1: 56-62.
14. Banker GS, Anderson NR. The Theory and Practice of Industrial Pharmacy: Tablet,Lachman, (3rded) Varghese Publishing House, Bombay. 1990; 3: 293-303.
15. Lee VHL, Controlled Drug Delivery Fundamentals and Applications: Influence of drug properties on design, Marcel Dekker, INC, and New York. 1987; 2: 16-29.
16. Manish R, Jayesh P, Siahboomi AR. Hydrophilic Matrices for Oral Extended Release: Influence of Fillers on Drug Release from HPMC Matrices. Pharma Times. 2010; 42(04): 67-73.
17. Kumar KP et al. Innovations in Sustained Release Drug Delivery System and Its Market Opportunities. J Chem Pharm Res. 2010; 2 1: 349-360.